Project overview
Despite significant advances in cancer treatment, many advanced childhood cancers—such as relapsed acute myeloid leukemia (AML), high-risk neuroblastoma, medulloblastoma (MB), and metastatic bone sarcomas, remain associated with poor survival rates. For example, relapsed AML survival rates are 20-40%, high-risk neuroblastoma is 50%, and relapsed neuroblastoma is less than 10%. Many of these cancers overexpress PRAME, a cancer-testis antigen, which presents a unique opportunity for targeted therapy. Autologous TCR-T cell therapies targeting PRAME have shown efficacy in adult melanoma, but for paediatric patients, allogeneic iNKT cells offer several advantages.
